Effect of buffer pH, buffer concentration and skin with or without enzyme inhibitors on the stability of [Arg8]-vasopressin

International Journal of Pharmaceutics

Volumn 197, Issue 1-2, 2000, Pages 87-93

  Bi, Mingda ^a   Singh, Jagdish ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Buffer concentration; Enzyme inhibitors; pH; Skin; Stability; Vasopressin

Indexed keywords

APROTININ; ARGIPRESSIN; BESTATIN; ENZYME INHIBITOR; LEUPEPTIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PH; PRIORITY JOURNAL; SKIN; SWINE;

ANIMALS; ARGININE VASOPRESSIN; BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; ENZYME INHIBITORS; HYDROGEN-ION CONCENTRATION; KINETICS; SKIN; SWINE; TEMPERATURE;

EID: 0033995102     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00459-7     Document Type: Article

References (21)

1. Advis J.P., Krause J.E., Mckelvy J.F. Luteinizing hormone releasing hormone peptidase activities in discrete hypothalamic regions and anterior pituitary of the rat: apparent regulation during the prepubertal period and first estrous cycle at puberty. Endocrinology. 110:1982;1238-1245.
2. Banga A.K., Katakam M., Mitra R. Transdermal iontophoretic delivery and degradation of vasopressin across human cadaver skin. Int. J. Pharm. 116:1995;211-216.
3. Bi M., Singh J. Degradation of luteinizing hormone releasing hormone in buccal, liver, nasal and skin tissues. Int. J. Pharm. 175:1998;269-273.
4. Bi M., Singh J. A HPLC method for quantification of Arginine containing vasopressin. J. Liq. Chromatogr. Relat. Technol. 22:1999;551-560.
5. Brange J., Langkjær L., Havelund S., Vølund A. Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm. Res. 9:1992;715-726.
6. Chimanlall G., Borchardt R.T. Kinetics of diketopeperazine formation using model peptides. J. Pharm. Sci. 87:1998;283-288.
7. Clarke G.I., Wood P., Merrick L., Lincoln D.W. Opiate inhibition of peptide release from the neurohumoral terminals of hypothalamic neurones. Nature. 282:1979;746-748.
8. Davis R., Forsling M.L., Slater D.H. The interrelationship between the release of renin and vasopressin as defined by orthostasis and propranolol. J. Clin. Invest. 60:1977;1438-1441.
9. Helm V.J., Muller B.W. Stability of the synthetic pentapeptide thymopentin in aqueous solution: effect of pH and buffer on degradation. Int. J. Pharm. 70:1991;29-34.
10. Hoitink, W.A., Beijnen, J.H., Bult, A., van der Houwen, Oeds, A.G.J., Nijholt, J., Underberg, W.J.M., 1996. Degradation kinetics of gonadorelin in aqueous solution, J. Pharm. Sci. 85, 1053-1059.
11. Lee K.C., Lee Y.J., Song H.M., Chun C.J., Deluca P.P. Degradation of synthetic salmon calcitonin in aqueous solution. Pharm. Res. 9:1992;1521-1523.
12. Lee V.H. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Syst. 5:1988;69-97.
13. Martin R.J., Denyer S.P., Hadgraft J. Skin metabolism of topically applied compound. Int. J. Pharm. 39:1987;23-32.
14. Morimoto K., Iwakura Y., Nakatani E., Miyazaki M., Tojima H. Effects of proteolytic enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of calcitonin in rats. J. Pharm. Pharmacol. 44:1992;216-218.
15. Morimoto K., Miyazaki M., Kakemi M. Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats. Int. J. Pharm. 113:1995;1-8.
16. Schmid R.D. Stabilized soluble enzymes. Adv. Biochem. Eng. 12:1979;41-118.
17. Shimizu K., Hoshino M. Application of vasopressin radioimmunoassay to clinical study: Role of vasopressin in hypo and hypernatremia and some other disorders of water metabolism. Contrib. Nephrol. 9:1978;42-60.
18. Wintroub U.B., Schechter B.N., Lazarus S.G., Kaempfer E.C., Schwartz B.L. Angiotensin-1 conversion by human and rat chymotryptic proteinases. J. Invest. Dermatol. 83:1984;336-339.
19. Yamamoto A., Fujita T., Muranishi S. Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors. J. Controlled Release. 41:1996;57-67.
20. Zaets L.T., Dolgina I.M., Muzykant I.L., Kotkina I.T., Nosova M.I. Changes in skin enzyme activity in experimental Burns. Vopr-Med-Khim. 6:1977;763-768.
21. Zhou X.H., Li Wan Po A. Peptide and protein drugs: I. Therapeutic applications, absorption and parenteral administration. Int. J. Pharm. 75:1991;97-115.